Int. J. Biosci.10( 3), 157-162, March 2017
Equine motor neuron disease (EMND) is a spontaneous neurologic disorder of adult horses which results from the degeneration of motor neurons in the spinal cord and brain stem. The etiology of EMND disease in the south Asian region is not well understood. To achieve the objective of the study, blood samples were collected from horses affected with EMND and DNA was purified by inorganic method. We sequenced both equine copper/zinc superoxide dismutase (SOD1) gene and equine ALS2 gene from 10 horses of Pakistani origin diagnosed with equine motor neuron disease (EMND) similar to amyotrophic lateral sclerosis (ALS) in humans. The 1359 nucleotidesSOD1 coding region in the horse genome encodes 453 amino acids residues. Equine SOD1 exhibits 84 and 79.9% sequence identity to the human homolog at the nucleotides and amino acids levels, respectively. As a result, no mutation was found in SOD1 in any of the 10 affected horses while in case of horse ALS2 gene that consists of 41 exons, two missense (p.Val83Ile; p.Leu305Arg) and one synonymous (p.Thr410Thr) genetic variants were identified in the ALS2 gene. In addition, 50 normal control samples of Pakistani horses were sequenced representing the 40% of both the missense mutations. Our results suggest that both of the genes were not involved in causing motor neuron disease in horses.
Ascherio A, Weisskopf MG, O’reilly EJ, Jacobs EJ, McCullough ML, Calle EE, Cudkowicz M, Thun MJ. 2005. Vitamin E intake and risk of amyotrophic lateral sclerosis. Annals Neurology 57(1), 104-10.
Cummings JF, George C, de Lahunta A, Fuher L, Valentine BA, Cooper BJ. 1990. Equine motor neuron disease. A preliminary report. Cornell Veterinarian 80, 357-379.
Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R, Siddique N, Mugnaini E, Siddique T. 2010. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Annals Neurology 67(6), 739-748.
Diez DCE, Zafra R, Acevedo LM, Perez J, Acosta I, Rivero JLL, Aguilera‐Tejero E. 2016. Eosinophilic Enteritis in Horses with Motor Neuron Disease. Journal of Veterinary Internal Medicine 30(3), 873–879.
Divers TJ, Mohammed HO, Cummings JF. 1997. Equine motor neuron disease. Veterinary Clinics of North America: Equine Practice 13, 97–105.
Lindsey RF, Anissa I, Jordi M, Yingjie L, Jason MH, Giovanni M, Jonathan DG. 2011.SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the SOD1 knockout mouse. Brain 134(Pt1), 196-209.
Green, SL, Tolwani RJ, Varma S, Quignon P, Galibert F, Cork LC. 2002. Structure, chromosomal location, and analysis of the canine Cu/Zn superoxide dismutase (SOD1) gene. Journal of Heredity 93(2), 119-124.
Grimberg J, Nawoschik S, Belluscio L, McKee R, Turck A, Eisenberg AA. 1989. Simple and efficient non-organic procedure for the isolation of genomic DNA from blood. Nucleic Acids Research 17, 83-90.
Gros-Louis F, Gaspar C, Rouleau G. 2006. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochimica et Biophysica Acta 1762(11-12), 956-972.
Kress JA, Kühnlein P, Winter P, Ludolph AC, Kassubek J, Müller U, Sperfeld AD. 2005. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Annals Neurology 58(5), 800-803.
Mohammed HO, Divers TJ, Summers BA, de Lahunta A. 2007. Vitamin E deficiency and risk of equine motor neuron disease. Acta Veterinaria Scandinavica 49(1), 17.
Mohammed HO, Divers TJ, Kwak J, Omar AH, White ME, de Lahunta A. 2012. Association of oxidative stress with motor neuron disease in horses. American Journal of Vetrinary Research 73(12), 1957-62.
Polack EW, Cummings JF, King J, Mohammed HO. 1998. Morphometric studies on equine motor neuron disease. Equine Veterinary Journal 30, 255-259.
Pramatarova A, Figlewicz DA, Krizus A, Han FY, Ceballos- Picot I, Nicole A, Dib M, Meininger V, Brown RH, Rouleau GA. 1995. Identification of new mutations in the Cu/Zn superoxide dismutase gene of patients with familial amyotrophic lateral sclerosis. American Journal of Human Genetics 56, 592- 596.
Rhee SG, Yang KS, Kang SW, Woo HA, Chang TS. 2005. Controlled elimination of intracellular H(2)O(2), regulation of peroxiredoxin, catalase, and glutathione peroxidase via post-translational modification. Antioxidants and Redox Signaling, 7(5-6), 619-26.
Rua-domenech DI, Wiedmann RM, Batt CA, Mohammed HO, Cummings JF, Divers TJ. 1994. Equine motor neuron disease: molecular epidemiologic studies. The kenya veterinarian 18(2), 290-292.
Saccon RA, Bunton-Stasyshyn RK, Elizabeth MC, Fratta P. 2013. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136(Pt 8), 2342-2358.
Siddiqi S, Foo JN, Vu A, Azim S, Silver DL, Mansoor A, Tay SK, Abbasi S, Hashmi AH, Janjua J, Khalid S, Tai ES, Yeo GW, Khor CC. 2014. A novel splice-site mutation in ALS2establishes the diagnosis of juvenile amyotrophic lateral sclerosis in a family with early onset anarthria and generalized dystonias. PLoS One 9(12), e113258.
Sillevis-Smitt PAE, De Jong JMBV. 1988. Animal models of amyotrophic lateral sclerosis and the spinal muscular atrophies. Jounal of Neurological Sciences 91, 231- 258.
Turner BJ, Baumer D, Parkinson NJ, Scaber J, Ansorge O, Talbot K. 2008. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. BMC Neuroscience 9, 104
Vehvilainen P, Koistinaho J, Gundars G. 2014. Mechanisms of mutant SOD1 induced mitochondrial toxicity in amyotrophic lateral sclerosis. Frontier in Cellular Neuroscience 8, 126.
Xie F, Cen ZD, Xiao JF, Luo W. 2015. Novel compound heterozygous ALS2 mutations in two Chinese siblings with infantile ascending hereditary spastic paralysis. Neurological Sciences 36(7), 1279-80.